Publications by authors named "Marta Chesi"

63Publications

Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination.

Leukemia 2020 01 22;34(1):245-256. Epub 2019 Aug 22.

Department of Pathology, Albert Einstein College of Medicine, Bronx, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0519-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923614PMC
January 2020

Inhibitors of the protein disulfide isomerase family for the treatment of multiple myeloma.

Leukemia 2019 04 12;33(4):1011-1022. Epub 2018 Oct 12.

Department of Cell and Molecular Pharmacology & Experimental Therapeutics, College of Medicine, Medical University of South Carolina, Charleston, SC, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41375-018-0263-1
Publisher Site
http://dx.doi.org/10.1038/s41375-018-0263-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194280PMC
April 2019

Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment.

Cancer Cell 2018 04;33(4):634-648.e5

Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, 4006 QLD, Australia; School of Medicine, University of Queensland, St Lucia 4006 QLD, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2018.02.007DOI Listing
April 2018

Antibodies Create Killer Bonds in Myeloma.

Cancer Cell 2017 03;31(3):305-307

Mayo Clinic in Arizona, Phoenix, AZ 85054, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2017.02.011DOI Listing
March 2017

Phase II trial of nab-paclitaxel in patients with relapsed or refractory multiple myeloma.

Am J Hematol 2016 12 11;91(12):E504-E505. Epub 2016 Oct 11.

Division of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24548DOI Listing
December 2016

Promiscuous mechanisms underlie the antitumor effects of thalidomide analogs.

Nat Med 2016 07;22(7):706-7

Mayo Clinic Comprehensive Cancer Center, Scottsdale, Arizona, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.4144DOI Listing
July 2016

UCHL1 is a biomarker of aggressive multiple myeloma required for disease progression.

Oncotarget 2015 Dec;6(38):40704-18

Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.5727DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747363PMC
December 2015

Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth.

Nat Commun 2015 Oct 12;6:8428. Epub 2015 Oct 12.

The Vontz Center for Molecular Studies, Department of Cancer and Cell Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms9428DOI Listing
October 2015

Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma.

Cancer Immunol Res 2015 Aug 4;3(8):881-90. Epub 2015 May 4.

Department of Medicine, Division of Hematology/Oncology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin. University of Wisconsin Carbone Cancer Center, Madison, Wisconsin.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0025-TDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527950PMC
August 2015

Erythroblast apoptosis and microenvironmental iron restriction trigger anemia in the VK*MYC model of multiple myeloma.

Haematologica 2015 Jun 24;100(6):834-841. Epub 2015 Feb 24.

Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy Fondazione Centro San Raffaele, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2014.118000DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450630PMC
June 2015

Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers.

Leuk Res 2014 Aug 2;38(8):948-54. Epub 2014 Jun 2.

Division of Cancer Research, Peter MacCallum Cancer Centre, St Andrew's Place, East Melbourne 3002, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville 3010, Australia; Department of Immunology, Monash University, Prahran 3181, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2014.05.010DOI Listing
August 2014

The drug vehicle and solvent N-methylpyrrolidone is an immunomodulator and antimyeloma compound.

Cell Rep 2014 May 9;7(4):1009-19. Epub 2014 May 9.

Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC 3002, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3002, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2014.04.008DOI Listing
May 2014

CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma.

Blood 2014 Jun 29;123(24):3770-9. Epub 2014 Apr 29.

Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY; Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2013-10-530964DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055924PMC
June 2014

TPL2 kinase regulates the inflammatory milieu of the myeloma niche.

Blood 2014 May 10;123(21):3305-15. Epub 2014 Apr 10.

Department of Medicine, Division of Hematology/Oncology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI; University of Wisconsin Carbone Cancer Center, Madison, WI;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-02-554071DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4046426PMC
May 2014

Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells.

Blood 2014 Jan 17;123(5):725-33. Epub 2013 Dec 17.

Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2013-08-524025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3907757PMC
January 2014

V. Molecular classification and risk stratification of myeloma.

Hematol Oncol 2013 Jun;31 Suppl 1:38-41

Mayo Clinic, Scottsdale, AZ 85259, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2065DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941196PMC
June 2013

Molecular pathogenesis of multiple myeloma: basic and clinical updates.

Int J Hematol 2013 Mar 28;97(3):313-23. Epub 2013 Feb 28.

Mayo Clinic Arizona, 13400 E Shea Blvd, Scottsdale, AZ 85259, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-013-1291-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3962846PMC
March 2013

Many multiple myelomas: making more of the molecular mayhem.

Hematology Am Soc Hematol Educ Program 2011 ;2011:344-53

Department of Hematology, Mayo Clinic, Scottsdale, AZ 85259, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2011.1.344DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903307PMC
April 2012

Epigenetics and microRNAs combine to modulate the MDM2/p53 axis in myeloma.

Cancer Cell 2010 Oct;18(4):299-300

Mayo Clinic in Arizona, Scottsdale, 85259, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2010.10.004DOI Listing
October 2010

Osteopontin dysregulation and lytic bone lesions in multiple myeloma.

Hematol Oncol 2007 Mar;25(1):16-20

Department of Medicine, Division of Hematology and Medical Oncology, Weill Medical College and Graduate School of Medical Sciences of Cornell University, New York, NY, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hon.803
Publisher Site
http://dx.doi.org/10.1002/hon.803DOI Listing
March 2007

Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma.

Blood 2004 May 8;103(9):3521-8. Epub 2004 Jan 8.

Department of Medicine, Weill Medical College and Graduate School of Medical Sciences, Cornell University, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2003-10-36
Publisher Site
http://dx.doi.org/10.1182/blood-2003-10-3650DOI Listing
May 2004

Differential regulation of IL-12 and IL-10 gene expression in macrophages by the basic leucine zipper transcription factor c-Maf fibrosarcoma.

J Immunol 2002 Nov;169(10):5715-25

Department of Microbiology and Immunology, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://www.jimmunol.org/content/169/10/5715.full.pdf
Web Search
http://dx.doi.org/10.4049/jimmunol.169.10.5715DOI Listing
November 2002